Evidence map›Paper›PMID 37380022›Full record

ArticleContemporary clinical trials2023

Feasibility of a positive psychology intervention (PATH) in allogeneic hematopoietic stem cell transplantation survivors: Randomized pilot trial design and methods.

Hermioni L Amonoo, Elizabeth Daskalakis, Emma C Deary, Christopher M Celano, Pia Maria Ghanime, Brian C Healy, Corey Cutler, William F Pirl, Elyse R Park, Lisa M Gudenkauf and 5 more

Open access · greenAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Contemporary clinical trials, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
5.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 7 institutions in 1 country.

Hermioni L AmonooDepartment of Psychosocial Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Psychiatry, Brigham and Women's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA. Electronic address: hermioni_amonoo@dfci.harvard.edu.
Elizabeth DaskalakisDepartment of Psychiatry, Brigham and Women's Hospital, Boston, MA, USA.
Emma C DearyDepartment of Psychiatry, Brigham and Women's Hospital, Boston, MA, USA.
Christopher M CelanoHarvard Medical School, Boston, MA, USA; Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA.
Pia Maria GhanimeHarvard Medical School, Boston, MA, USA; Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA.
Brian C HealyHarvard Medical School, Boston, MA, USA; Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA.
Corey CutlerHarvard Medical School, Boston, MA, USA; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA.
William F PirlDepartment of Psychosocial Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Psychiatry, Brigham and Women's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
Elyse R ParkHarvard Medical School, Boston, MA, USA; Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA.
Lisa M GudenkaufDepartment of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, USA.
Heather S L JimDepartment of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, USA.
Lara N TraegerDepartment of Psychology, University of Miami, Miami, FL, USA.
Thomas W LeBlancDuke Cancer Institute, Durham, NC, USA; Department of Medicine, Division of Hematologic Malignancies and Cellular Therapy, Duke University School of Medicine, Durham, NC, USA.
Areej El-JawahriHarvard Medical School, Boston, MA, USA; Mass General Cancer Center, Massachusetts General Hospital, Boston, MA, USA.
Jeff C HuffmanHarvard Medical School, Boston, MA, USA; Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA.
Brigham and Women's Hospital · USMassachusetts General Hospital · USHarvard University · USMoffitt Cancer Center · USDana-Farber Cancer Institute · USDuke Cancer InstituteUniversity of Miami · US

Funding

A novel behavioral intervention to promote adherence in heart failureR01HL155301 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI CELANO, CHRISTOPHER M · 2021 to 2025
$3.8M
Developing a positive psychology intervention to improve cardiac health behaviorsR01HL113272 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI HUFFMAN, JEFF C · 2013 to 2017
$2.6M
A Positive Psychology Intervention for Allogeneic Stem Cell Transplant Patients.K08CA251654 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI AMONOO, HERMIONI L. · 2020 to 2024
$1.3M
AHRQ HHS T32 HS013853NCI NIH HHS K08 CA251654NHLBI NIH HHS R01 HL113272NHLBI NIH HHS R01 HL155301
6 · The paper itself

Abstract

backgroundAlthough patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) experience low levels of positive psychological well-being (PPWB), interventions that specifically boost PPWB in this population are lacking.

objectiveTo describe the methods of a randomized controlled trial (RCT) designed to assess the feasibility, acceptability, and preliminary efficacy of a positive psychology intervention (PATH) tailored to the unique needs of HSCT survivors and aimed to decrease anxiety and depression symptoms and boost quality of life (QOL).

methodsWe will conduct a single-institution RCT of a novel nine-week phone-delivered manualized positive psychology intervention compared to usual transplant care in 70 HSCT survivors. Allogeneic HSCT survivors at 100 days post-HSCT are eligible for the study. The PATH intervention, tailored to the needs of HSCT survivors in the acute recovery phase, focuses on gratitude, strengths, and meaning. Our primary aims are to determine feasibility (e.g., session completion, rate of recruitment) and acceptability (e.g., weekly session ratings). Our secondary aim is to test the preliminary efficacy of the intervention on patient-reported outcomes (e.g., anxiety symptoms, QOL). DISCUSSION: If the PATH intervention is feasible, a larger randomized, controlled efficacy trial will be indicated. Additionally, we anticipate that the results from this RCT will guide the development of other clinical trials and larger efficacy studies of positive psychology interventions in vulnerable oncological populations beyond HSCT.

Indexed as

Hematopoietic Stem Cell TransplantationPsychology, PositiveFeasibility StudiesHumansPilot ProjectsQuality of LifeRandomized Controlled Trials as TopicSurvivorsHematologic malignanciesHematopoietic stem cell transplantationPositive psychologyPsycho-oncologyRandomized controlled trial

Identifiers

PMID37380022
PMCPMC10839810
OpenAlexW4382051614

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.